Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective tissues, synovial fluid, and the extracellular matrix. Exogenous preparations vary significantly by formulation (topical, ophthalmic, intra-articular), molecular weight, and intended use.
## Primary Indications
* **Intra-articular:** Osteoarthritis (OA) of the knee (when non-pharmacologic or analgesic therapy fails).
* **Ophthalmic:** Dry eye disease (lubricant).
* **Topical/Dermal:** Wound healing, skin hydration, and aesthetic filler.
## Adult Dosing
* **Intra-articular (Knee OA):**
* *Sodium Hyaluronate (e.g., Hyalgan):* 20 mg (2 mL) weekly for 5 injections.
* *Hylan G-F 20 (e.g., Synvisc):* 16 mg (2 mL) weekly for 3 injections.
* *Hylan G-F 20 (e.g., Synvisc-One):* 48 mg (6 mL) once.
* *Cross-linked HA (e.g., Euflexxa):* 20 mg (2 mL) weekly for 3 injections.
* **Ophthalmic:** 1–2 drops in affected eye(s) as needed or per manufacturer label (ranges from 0.1% to 0.4% solutions).
* **Dermal/Topical:** Apply sparingly to affected area 1–2 times daily as directed by product labeling.
## Pediatric Dosing
* **Intra-articular:** Not established. Limited safety data in children.
* **Ophthalmic/Topical:** Use is considered off-label; generally safe for pediatric use as a lubricant, though frequency should be guided by a pediatrician or ophthalmologist.
## Dose Adjustments
* **Renal/Hepatic:** No specific adjustments required for local formulations (intra-articular/topical/ophthalmic).
* **Geriatric:** No specific adjustments; caution in patients with history of joint infection or systemic inflammation.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Active infections in or near the target joint (intra-articular use).
* Known hypersensitivity to avian proteins (if the HA product is avian-derived).
## Adverse Effects
* **Intra-articular:** Injection site pain, joint swelling, joint effusion, arthralgia, and rare acute inflammatory reactions (pseudoseptic arthritis).
* **Ophthalmic:** Transient blurred vision, ocular irritation or redness.
* **Dermal:** Localized erythema or allergic contact dermatitis (rare).
## Key Drug Interactions
* Minimal systemic absorption for most formulations. Avoid concomitant administration of quaternary ammonium solutions (e.g., benzalkonium chloride) in ophthalmic preparations as they may cause precipitation.
## Monitoring
* **Intra-articular:** Monitor for signs of local infection or severe inflammation (e.g., significant heat, redness, or increased pain >48 hours post-injection).
* **Efficacy:** Assess pain relief and functional improvement in joint mobility post-injection series.
## Clinical Pearls
* **Site Specificity:** Intra-articular injections must be performed using strict aseptic technique.
* **Not a Cure:** HA is considered symptom-modifying rather than disease-modifying for osteoarthritis.
* **Product Variance:** HA products vary by cross-linking technology and molecular weight, which affects residence time in the joint. Ensure brand-specific dosing is followed, as regimens are not interchangeable.
* **Post-Injection:** Patients should avoid strenuous activity (strenuous leg exercise, jogging, heavy lifting) for 48 hours following intra-articular injection.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and usage protocols may vary based on local institutional guidelines, specific product manufacturing, and patient-specific factors. Always consult the latest prescribing information (package insert) and clinical guidelines before prescribing or administering any medication.
